Office of the Commissioner; Statement of Organization, Functions, and Delegations of Authority, 34956-34957 [2017-15443]
Download as PDF
<![CDATA[
34956
Federal Register / Vol. 82, No. 143 / Thursday, July 27, 2017 / Notices
Request for Comments
In accordance with the Paperwork
Reduction Act, comments on AHRQ’s
information collection are requested
with regard to any of the following: (a)
Whether the proposed collection of
information is necessary for the proper
performance of AHRQ health care
research and health care information
dissemination functions, including
whether the information will have
practical utility; (b) the accuracy of
AHRQ’s estimate of burden (including
hours and costs) of the proposed
collection(s) of information; (c) ways to
enhance the quality, utility and clarity
of the information to be collected; and
(d) ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Sharon B. Arnold,
Deputy Director.
[FR Doc. 2017–15798 Filed 7–26–17; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Proposed Projects
Title: Federal Case Registry (FCR)
OMB No.: 0970–0421.
Description: Established within the
Federal Parent Locator Service (FPLS)
on October 1, 1998, the Federal Case
Registry (FCR) is a database that
contains basic case and participant data
from each of the State Case Registries
(SCRs). The SCRs are central registries
of child support cases and orders in
each state.
The FCR is a national database that
includes all child support cases handled
by state child support agencies (referred
to as IV–D cases), and all support orders
established or modified on or after
October 1, 1998 (referred to as non-IV–
D orders). It assists states in locating
parties that live in different states to
establish, modify, or enforce child
support obligations; establish paternity;
enforce state law regarding parental
kidnapping; and establish or enforce
child custody or visitation
determinations.
When a state sends the FCR
information about persons in a new case
or child support order, this new
information is automatically compared
to existing person information in the
FCR. If matches are found, the FPLS
notifies all appropriate state child
support enforcement agencies of the
record match. In this way, a state will
know if another state has a case or
support order with participants in
common with it, and can take
appropriate action.
The information collection activities
pertaining to the FCR are authorized by:
(1) 42 U.S.C. 653(h), requiring the
establishment of the Federal Case
Registry (FCR) within the Federal Parent
Locator Service (FPLS). (2) 42 U.S.C.
654A(e), requiring State child support
agencies to include a State Case Registry
(SCR) in the state’s automated system.
(3) 42 U.S.C. 654A(f)(1), requiring states
to conduct information comparison
activities between the SCR and the FCR.
Respondents: State Child Support
Agencies.
ANNUAL BURDEN ESTIMATES
Number of
responses
per
respondent
Number of
respondents
Information collection title
Average burden
hours per response
Total burden
hours
Federal Case Registry ...........................................................................
54
1 151
2 minutes 2 ..............
272
Total ................................................................................................
........................
........................
.................................
272
1 Number
mstockstill on DSK30JT082PROD with NOTICES
of responses per respondent is based on the assumption that half of the states submit weekly (52 responses) and half submit daily
(250 responses).
2 Estimated transmission time is 2 minutes. For the hourly calculation, use 2/60.
Estimated Total Annual Burden
Hours: 272.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Planning, Research and Evaluation, 330
C Street SW., Washington, DC 20201,
Attention Reports Clearance Officer. All
requests should be identified by the
information collection. Email address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
VerDate Sep<11>2014
19:17 Jul 26, 2017
Jkt 241001
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Email: OIRA_
SUBMISSION@OMB.EOP.GOV, Attn:
Desk Officer for the Administration for
Children and Families.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Office of the Commissioner; Statement
of Organization, Functions, and
Delegations of Authority
AGENCY:
Bob Sargis,
Reports Clearance Officer.
Food and Drug Administration,
HHS.
ACTION:
Notice.
[FR Doc. 2017–15822 Filed 7–26–17; 8:45 am]
The Food and Drug
Administration (FDA), Office of the
Medical Products and Tobacco (OMPT),
has modified its structure. This new
organizational structure was approved
by the Secretary of Health and Human
Services on December 22, 2016, and
became effective on that date.
SUMMARY:
BILLING CODE 4184–41–P
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
E:\FR\FM\27JYN1.SGM
27JYN1
Federal Register / Vol. 82, No. 143 / Thursday, July 27, 2017 / Notices
FOR FURTHER INFORMATION CONTACT:
Rachel Sherman, M.D., Deputy
Commissioner for Medical Products and
Tobacco, Office of Medical Products and
Tobacco, Food and Drug
Administration, White Oak Bldg. 1,
HFD–40, Room 2307, Silver Spring,
Maryland, 20993. Phone: 240–402–
4474.
SUPPLEMENTARY INFORMATION:
mstockstill on DSK30JT082PROD with NOTICES
I. Introduction
Part D, Chapter D–B, (Food and Drug
Administration), the Statement of
Organization, Functions, and
Delegations of Authority for the
Department of Health and Human
Services (35 FR 3685, February 25,
1970; 60 FR 56606, November 9, 1995;
64 FR 36361, July 6, 1999; 72 FR 50112,
August 30, 2007; 74 FR 41713, August
18, 2009; and 76 FR 45270, July 28,
2011) is amended to reflect the
reorganization of the Office of Medical
Products and Tobacco.
This reorganization establishes the
Oncology Center of Excellence (OCE) to
optimize an integrated cross-center
regulatory approach and enhance the
coordination of medical product
development in oncology. Located
within OMPT, OCE will work closely
with the directors of the centers, the
Center for Biologics Evaluation and
Research (CBER), the Center for Drug
Evaluation and Research (CDER), the
Center for Devices and Radiological
Health (CDRH), and all FDA staff
involved in oncology efforts. The OCE
will be responsible, in accordance with
an Inter-Center Agreement between
OCE, CBER, CDER, and CDRH, for the
clinical portion of medical oncology and
malignant hematology applications
involving drugs, biologics, and devices.
Other functions of the OCE include:
Harmonization of cancer-specific
regulatory approaches; coordination of
oncology-specific regulatory science
initiatives and outreach;
implementation of cross-center
oncology-focused meetings; stakeholder
engagement to the external community
of other government agencies, industry,
academia, professional societies, and
patient advocacy groups; and
communication with international
regulatory agencies.
The Food and Drug Administration
(FDA), Office of Medical Products and
Tobacco (OMPT), has been restructured
as follows:
DKK. Organization. The Office of
Medical Products and Tobacco is
headed by the Deputy Commissioner for
Medical Products and Tobacco and
includes the following organizational
units and FDA Centers that, under the
VerDate Sep<11>2014
19:17 Jul 26, 2017
Jkt 241001
current structure, officially report to
OMPT:
Office of Medical Products and Tobacco
(DKK)
Office of Special Medical Products
(DKKA)
Office of Pediatric Therapeutics
(DKKAA)
Office of Orphan Products Development
(DKKAB)
Office of Combination Products
(DKKAD)
Center for Biologics Evaluation and
Research (DKKB)
Center for Tobacco Products (DKKI)
Center for Drug Evaluation and Research
(DKKN)
Center for Devices and Radiological
Health (DKKW)
Oncology Center of Excellence (DKKX)
II. Delegations of Authority
Pending further delegation, directives,
or orders by the Commissioner of Food
and Drugs, all delegations and
redelegations of authority made to
officials and employees of affected
organizational components will
continue in them or their successors
pending further redelegations, provided
they are consistent with this
reorganization.
III. Electronic Access
This reorganization is reflected in
FDA’s Staff Manual Guide (SMG).
Persons interested in seeing the
complete Staff Manual Guide can find it
on FDA’s Web site at: https://
www.fda.gov/AboutFDA/
ReportsManualsForms/
StaffManualGuides/default.htm.
Authority: 44 U.S.C. 3101.
Dated: July 17, 2017.
Thomas E. Price,
Secretary of Health and Human Services.
[FR Doc. 2017–15443 Filed 7–26–17; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Interest Rate on Overdue
Debts
Section 30.18 of the Department of
Health and Human Services’ claims
collection regulations (45 CFR part 30)
provides that the Secretary shall charge
an annual rate of interest, which is
determined and fixed by the Secretary
of the Treasury after considering private
consumer rates of interest on the date
that the Department of Health and
Human Services becomes entitled to
recovery. The rate cannot be lower than
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
34957
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
Maturities’’ unless the Secretary waives
interest in whole or part, or a different
rate is prescribed by statute, contract, or
repayment agreement. The Secretary of
the Treasury may revise this rate
quarterly. The Department of Health and
Human Services publishes this rate in
the Federal Register.
The current rate of 101⁄8%, as fixed by
the Secretary of the Treasury, is certified
for the quarter ended June 30, 2017.
This rate is based on the Interest Rates
for Specific Legislation, ‘‘National
Health Services Corps Scholarship
Program (42 U.S.C. 254o(b)(1)(A))’’ and
‘‘National Research Service Award
Program (42 U.S.C. 288(c)(4)(B)).’’ This
interest rate will be applied to overdue
debt until the Department of Health and
Human Services publishes a revision.
Dated: July 13, 2017.
David C. Horn,
Director, Office of Financial Policy and
Reporting.
[FR Doc. 2017–15854 Filed 7–26–17; 8:45 am]
BILLING CODE 4150–04–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Nonhuman Primate (NHP)
Core Functional Genomics Laboratory for
AIDS Vaccine Research and Development.
Date: August 31, 2017.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
E:\FR\FM\27JYN1.SGM
27JYN1
]]>Agencies
[Federal Register Volume 82, Number 143 (Thursday, July 27, 2017)]
[Notices]
[Pages 34956-34957]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-15443]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Office of the Commissioner; Statement of Organization, Functions,
and Delegations of Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA), Office of the Medical
Products and Tobacco (OMPT), has modified its structure. This new
organizational structure was approved by the Secretary of Health and
Human Services on December 22, 2016, and became effective on that date.
[[Page 34957]]
FOR FURTHER INFORMATION CONTACT: Rachel Sherman, M.D., Deputy
Commissioner for Medical Products and Tobacco, Office of Medical
Products and Tobacco, Food and Drug Administration, White Oak Bldg. 1,
HFD-40, Room 2307, Silver Spring, Maryland, 20993. Phone: 240-402-4474.
SUPPLEMENTARY INFORMATION:
I. Introduction
Part D, Chapter D-B, (Food and Drug Administration), the Statement
of Organization, Functions, and Delegations of Authority for the
Department of Health and Human Services (35 FR 3685, February 25, 1970;
60 FR 56606, November 9, 1995; 64 FR 36361, July 6, 1999; 72 FR 50112,
August 30, 2007; 74 FR 41713, August 18, 2009; and 76 FR 45270, July
28, 2011) is amended to reflect the reorganization of the Office of
Medical Products and Tobacco.
This reorganization establishes the Oncology Center of Excellence
(OCE) to optimize an integrated cross-center regulatory approach and
enhance the coordination of medical product development in oncology.
Located within OMPT, OCE will work closely with the directors of the
centers, the Center for Biologics Evaluation and Research (CBER), the
Center for Drug Evaluation and Research (CDER), the Center for Devices
and Radiological Health (CDRH), and all FDA staff involved in oncology
efforts. The OCE will be responsible, in accordance with an Inter-
Center Agreement between OCE, CBER, CDER, and CDRH, for the clinical
portion of medical oncology and malignant hematology applications
involving drugs, biologics, and devices. Other functions of the OCE
include: Harmonization of cancer-specific regulatory approaches;
coordination of oncology-specific regulatory science initiatives and
outreach; implementation of cross-center oncology-focused meetings;
stakeholder engagement to the external community of other government
agencies, industry, academia, professional societies, and patient
advocacy groups; and communication with international regulatory
agencies.
The Food and Drug Administration (FDA), Office of Medical Products
and Tobacco (OMPT), has been restructured as follows:
DKK. Organization. The Office of Medical Products and Tobacco is
headed by the Deputy Commissioner for Medical Products and Tobacco and
includes the following organizational units and FDA Centers that, under
the current structure, officially report to OMPT:
Office of Medical Products and Tobacco (DKK)
Office of Special Medical Products (DKKA)
Office of Pediatric Therapeutics (DKKAA)
Office of Orphan Products Development (DKKAB)
Office of Combination Products (DKKAD)
Center for Biologics Evaluation and Research (DKKB)
Center for Tobacco Products (DKKI)
Center for Drug Evaluation and Research (DKKN)
Center for Devices and Radiological Health (DKKW)
Oncology Center of Excellence (DKKX)
II. Delegations of Authority
Pending further delegation, directives, or orders by the
Commissioner of Food and Drugs, all delegations and redelegations of
authority made to officials and employees of affected organizational
components will continue in them or their successors pending further
redelegations, provided they are consistent with this reorganization.
III. Electronic Access
This reorganization is reflected in FDA's Staff Manual Guide (SMG).
Persons interested in seeing the complete Staff Manual Guide can find
it on FDA's Web site at: https://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/default.htm.
Authority: 44 U.S.C. 3101.
Dated: July 17, 2017.
Thomas E. Price,
Secretary of Health and Human Services.
[FR Doc. 2017-15443 Filed 7-26-17; 8:45 am]
BILLING CODE P
